Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366392625> ?p ?o ?g. }
- W4366392625 endingPage "610" @default.
- W4366392625 startingPage "610" @default.
- W4366392625 abstract "Neuroprotective drugs to protect the brain against cerebral ischemia and reperfusion (I/R) injury are urgently needed. Mammalian cell-produced recombinant human erythropoietin (rhuEPOM) has been demonstrated to have excellent neuroprotective functions in preclinical studies, but its neuroprotective properties could not be consistently translated in clinical trials. The clinical failure of rhuEPOM was thought to be mainly due to its erythropoietic activity-associated side effects. To exploit its tissue-protective property, various EPO derivatives with tissue-protective function only have been developed. Among them, asialo-rhuEPO, lacking terminal sialic acid residues, was shown to be neuroprotective but non-erythropoietic. Asialo-rhuEPO can be prepared by enzymatic removal of sialic acid residues from rhuEPOM (asialo-rhuEPOE) or by expressing human EPO gene in glycoengineered transgenic plants (asialo-rhuEPOP). Both types of asialo-rhuEPO, like rhuEPOM, displayed excellent neuroprotective effects by regulating multiple cellular pathways in cerebral I/R animal models. In this review, we describe the structure and properties of EPO and asialo-rhuEPO, summarize the progress on neuroprotective studies of asialo-rhuEPO and rhuEPOM, discuss potential reasons for the clinical failure of rhuEPOM with acute ischemic stroke patients, and advocate future studies needed to develop asialo-rhuEPO as a multimodal neuroprotectant for ischemic stroke treatment." @default.
- W4366392625 created "2023-04-21" @default.
- W4366392625 creator A5014741937 @default.
- W4366392625 creator A5015612883 @default.
- W4366392625 creator A5015864729 @default.
- W4366392625 creator A5022373246 @default.
- W4366392625 creator A5061355261 @default.
- W4366392625 date "2023-04-18" @default.
- W4366392625 modified "2023-09-25" @default.
- W4366392625 title "Asialo-rhuEPO as a Potential Neuroprotectant for Ischemic Stroke Treatment" @default.
- W4366392625 cites W1498420568 @default.
- W4366392625 cites W1503620498 @default.
- W4366392625 cites W1504583940 @default.
- W4366392625 cites W1505165073 @default.
- W4366392625 cites W1533672300 @default.
- W4366392625 cites W1557794136 @default.
- W4366392625 cites W1565541955 @default.
- W4366392625 cites W1573653133 @default.
- W4366392625 cites W1573656797 @default.
- W4366392625 cites W1579220807 @default.
- W4366392625 cites W1583080856 @default.
- W4366392625 cites W1604651284 @default.
- W4366392625 cites W1660702278 @default.
- W4366392625 cites W1814267858 @default.
- W4366392625 cites W1855047800 @default.
- W4366392625 cites W1964818405 @default.
- W4366392625 cites W1966491512 @default.
- W4366392625 cites W1967334494 @default.
- W4366392625 cites W1970188265 @default.
- W4366392625 cites W1970325360 @default.
- W4366392625 cites W1973596659 @default.
- W4366392625 cites W1974716477 @default.
- W4366392625 cites W1976869427 @default.
- W4366392625 cites W1977152335 @default.
- W4366392625 cites W1978726693 @default.
- W4366392625 cites W1979564275 @default.
- W4366392625 cites W1981317595 @default.
- W4366392625 cites W1984053671 @default.
- W4366392625 cites W1986436077 @default.
- W4366392625 cites W1986780249 @default.
- W4366392625 cites W1989109435 @default.
- W4366392625 cites W1991317976 @default.
- W4366392625 cites W1993610142 @default.
- W4366392625 cites W1997122023 @default.
- W4366392625 cites W2007124202 @default.
- W4366392625 cites W2013257758 @default.
- W4366392625 cites W2014357012 @default.
- W4366392625 cites W2014621947 @default.
- W4366392625 cites W2017479007 @default.
- W4366392625 cites W2017567201 @default.
- W4366392625 cites W2017769476 @default.
- W4366392625 cites W2018039414 @default.
- W4366392625 cites W2021482099 @default.
- W4366392625 cites W2022805013 @default.
- W4366392625 cites W2025960909 @default.
- W4366392625 cites W2026116544 @default.
- W4366392625 cites W2026262250 @default.
- W4366392625 cites W2032926075 @default.
- W4366392625 cites W2039728906 @default.
- W4366392625 cites W2041803434 @default.
- W4366392625 cites W2043058596 @default.
- W4366392625 cites W2043633787 @default.
- W4366392625 cites W2047731143 @default.
- W4366392625 cites W2047980129 @default.
- W4366392625 cites W2050584234 @default.
- W4366392625 cites W2051130316 @default.
- W4366392625 cites W2055184396 @default.
- W4366392625 cites W2056415779 @default.
- W4366392625 cites W2056554399 @default.
- W4366392625 cites W2056702365 @default.
- W4366392625 cites W2058141781 @default.
- W4366392625 cites W2058316500 @default.
- W4366392625 cites W2058992974 @default.
- W4366392625 cites W2059275934 @default.
- W4366392625 cites W2064655482 @default.
- W4366392625 cites W2066816139 @default.
- W4366392625 cites W2066968724 @default.
- W4366392625 cites W2067391573 @default.
- W4366392625 cites W2071719170 @default.
- W4366392625 cites W2071723765 @default.
- W4366392625 cites W2072650744 @default.
- W4366392625 cites W2074406070 @default.
- W4366392625 cites W2074901593 @default.
- W4366392625 cites W2076161738 @default.
- W4366392625 cites W2077147171 @default.
- W4366392625 cites W2078022765 @default.
- W4366392625 cites W2081246522 @default.
- W4366392625 cites W2084613632 @default.
- W4366392625 cites W2084907542 @default.
- W4366392625 cites W2087177155 @default.
- W4366392625 cites W2088051520 @default.
- W4366392625 cites W2090969188 @default.
- W4366392625 cites W2095473686 @default.
- W4366392625 cites W2099348212 @default.
- W4366392625 cites W2100072314 @default.
- W4366392625 cites W2101017316 @default.
- W4366392625 cites W2103320383 @default.
- W4366392625 cites W2103530688 @default.